Variability in zidovudine serum concentrations

Pharmacotherapy

Volumn 16, Issue 6 I, 1996, Pages 1154-1158

  Fletcher, Courtney V ^a,c   Balfour Jr , Henry H ^b  

^a University of Minnesota   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZIDOVUDINE;

ARTICLE; BODY WEIGHT; COMPARTMENT MODEL; COMPUTER SIMULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS;

ADULT; ANTIVIRAL AGENTS; COMPUTER SIMULATION; HUMANS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; ZIDOVUDINE;

EID: 0029827117     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Sande MA, Carpenter CCJ, Cobbs G, Holmes KK, Sanford JP. Antiretroviral therapy for adult HIV-infected patients: recommendations from a state-of-the-art conference. JAMA 1993;270:2583-9.
2. D'Argenio DZ, Schumitzky A, Wolf W. Simulation of linear compartment models with application to nuclear medicine kinetic modeling. Comput Methods Prog Biomed 1988;27:47-54.
3. Fletcher CV, Rhame FS, Beatty CC, Simpson M, Balfour HH Jr. Comparative pharmacokinetics of zidovudine in healthy volunteers and in patients with AIDS with and without hepatic disease. Pharmacotherapy 1992;12:429-34.
4. Robbins BL, Rodman J, McDonald C, Srivivas RV, Flynn PM, Fridland A. Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells. Antimicrob Agents Chemother 1995;38:115-21.
5. Mentre F, Escolano S, Diquet B, Golmard JL, Mallet A. Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationships to long-term efficacy and toxicity. Eur J Clin Pharmacol 1993;45:397-407.
6. Blum MR, Liao SHT, Good SS, de Miranda P. Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med 1988;85(suppl 2A):189-94.
7. Sahai J, Gallicano K, Ormsby E, Garber G, Cameron DW. Relationship between body weight, body surface area and serum zidovudine pharmacokinetic parameters in adult, male HIV-infected patients. AIDS 1994;8:793-6.
8. Unadkat J, Tartaglione T, Opheim K, et al. Estimation of population pharmacokinetic parameters of zidovudine (ZDV or AZT) from AIDS patients enrolled in a phase II/III trial. In: Proceedings of the Fourth International Conference on AIDS, Stockholm, Sweden, June 12-16, 1992.
9. Rosenbaum SE, Carter AA, Drusano GL, Dudley MN, and the VA Cooperative Studies Group. Population pharmacokinetics of zidovudine in symptomatic patients with HIV-infection: update from the VA cooperative study #298. In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, September 17, 1995.
10. Burger DM, Meenhorst PL, ten Napal CHH, et al. Pharmacokinetic variability of zidovudine in HIV-infected individuals: subgroup analysis and drug interactions. AIDS 1994;8:1683-9.
11. Drusano GL, Balis FM, Gitterman SR, et al. Quantitative relationships between zidovudine exposure and efficacy and toxicity. Antimicrob Agents Chemother 1994;38:1726-31.
12. Balis FM, Pizzo PA, Murphy RF, et al. The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann Intern Med 1989;110:279-85.